Find Your Way Forward Explore the AdaptDx Pro and TheiaFrom the comfort of your home or office.Visit our virtual exhibit
The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Protect Your Eyesight
Talking to your eye doctor about risk factors or trouble seeing at night may help detect macular degeneration early enough to delay or prevent blindness.
Breakthrough Technology Meets High-Touch Patient Care
The advanced technology of the AdaptDx Pro™ can help you detect AMD at the subclinical stage and manage this progressive disease to prevent unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instruction every time.
Latest News & Upcoming EventsView More
Even amid COVID-19 worries, caring for patients with retinal disease is a necessity. Optometry needs to focus on essential office visits moving forward, including patients with macular disease.
"Open yourself up to learning something new. Education truly is the key to being a trailblazer," says Frances Bynum, OD in her latest piece dedicated to conquering the challenges ODs face with subclinical AMD detection.
The AdaptDx Pro is truly a revolutionary way to quickly and effectively measure dark adaptation (to help detect subclinical AMD) in virtually any setting, without taking up too much staff or doctor time.